• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

    10/31/23 1:36:43 PM ET
    $AIRE
    $ANET
    $ANVS
    $ATXI
    Real Estate
    Finance
    Computer Communications Equipment
    Telecommunications
    Get the next $AIRE alert in real time by email

    Gainers

    • SciSparc Ltd. (NASDAQ:SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for Combination of Opioids and N-Acylethanolamines for pain treatment.
    • Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) gained 53.1% to $0.3264 after the company received an Innovation Technology contract from Vizient for its novel AI-driven precision heart disease tests.
    • Verve Therapeutics, Inc. (NASDAQ:VERV) jumped 27% to $11.95. Eli Lilly said it will acquire rights under Beam Therapeutics’ amended collaboration and license agreement with Verve, including rights to co-develop and co-commercialize Verve's base editing programs for cardiovascular disease.
    • BioVie Inc. (NASDAQ:BIVI) rose 23.6% to $4.7840.
    • Wolfspeed, Inc. (NYSE:WOLF) jumped 22.7% to $34.02 after the company reported first-quarter earnings.
    • Repligen Corporation (NASDAQ:RGEN) gained 20.5% to $137.65 following better-than-expected results.
    • Mullen Automotive, Inc. (NASDAQ:MULN) rose 20.1% to $0.3051.
    • YanGuFang International Group Co., Ltd. (NASDAQ:YGF) gained 19.5% to $2.81.
    • Shutterstock, Inc. (NYSE:SSTK) climbed 18.6% to $40.71 after the company posted upbeat third-quarter results and raised FY23 outlook.
    • Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) rose 17.7% to $23.21 following third-quarter results.
    • Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares gained 17.5% to $0.1090 after the company announced it has completed the divestiture of AVTX-800 Series.
    • Pinterest, Inc. (NYSE:PINS) shares rose 16.9% to $29.34 after the company reported better-than-expected third-quarter financial results and issued guidance.
    • Two Harbors Investment Corp. (NYSE:TWO) climbed 16.8% to $11.74 following quarterly results.
    • Conduit Pharmaceuticals Inc. (NASDAQ:CDT) rose 16.5% to $1.83.
    • Femasys Inc. (NASDAQ:FEMY) gained 16.5% to $1.62.
    • Modular Medical, Inc. (NASDAQ:MODD) jumped 15% to $1.23.
    • Evaxion Biotech A/S (NASDAQ:EVAX) climbed 14.8% to $1.09.
    • Insperity, Inc. (NYSE:NSP) gained 14.3% to $110.31 following upbeat results.
    • EUDA Health Holdings Limited (NASDAQ:EUDA) rose 14.2% to $0.86.
    • Perficient, Inc. (NASDAQ:PRFT) gained 13.6% to $58.51 following strong quarterly sales.
    • Granite Construction Incorporated (NYSE:GVA) jumped 13.4% to $38.92 following strong quarterly results.
    • The Vita Coco Company, Inc. (NASDAQ:COCO) gained 12.7% to $26.34 following upbeat earnings.
    • Beam Therapeutics Inc. (NASDAQ:BEAM) climbed 12.5% to $21.50 after Eli Lilly agreed to acquire certain rights under Beam's agreement with Verve Therapeutics.
    • Pulmonx Corporation (NASDAQ:LUNG) gained 12.2% to $8.85 as the company posted third-quarter results and raised 2023 revenue outlook.
    • Otter Tail Corporation (NASDAQ:OTTR) rose 11.3% to $77.63 after the company posted third-quarter results and raised 2023 EPS guidance.
    • TransCode Therapeutics, Inc. (NASDAQ:RNAZ) shares gained 11.2% to $0.4001 after the company announced it is withdrawing the underwritten public offering of its common stock.
    • Arista Networks, Inc. (NYSE:ANET) rose 10.8% to $194.69 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates.
    • Ryerson Holding Corporation (NYSE:RYI) climbed 8.2% to $29.76 following third-quarter results.
    • Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) rose 5.5% to $0.4908. On Oct. 24, 2023, Shuttle Pharmaceuticals entered into an exclusive licensing agreement with Georgetown University.
    • HomeStreet, Inc. (NASDAQ:HMST) gained 3.1% to $4.71 following better-than-expected third-quarter earnings.

    Losers

    • Kintara Therapeutics, Inc. (NASDAQ:KTRA) shares dipped 76.7% to $0.8901. The company announced that its drug VAL-083 did not outperform existing treatments for glioblastoma, a severe brain cancer.
    • Galera Therapeutics, Inc. (NASDAQ:GRTX) fell 55.8% to $0.0934 after the company said GRECO-2 trial did not pass futility analysis.
    • reAlpha Tech Corp. (NASDAQ:AIRE) fell 53.5% to $23.17.
    • Sientra, Inc. (NASDAQ:SIEN) declined 48% to $0.76 after the company reported preliminary unaudited third-quarter financial results.
    • Sarepta Therapeutics, Inc. (NASDAQ:SRPT) fell 42.3% to $62.16 after the company said EMBARK did not meet the primary endpoint.
    • Avenue Therapeutics, Inc. (NASDAQ:ATXI) declined 34.4% to $0.23 as the company announced pricing of $5 million public offering.
    • PetMed Express, Inc. (NASDAQ:PETS) fell 33.2% to $6.14 after reporting weaker-than-expected second-quarter sales.
    • Tempo Automation Holdings, Inc. (NASDAQ:TMPO) shares fell 32.8% to $0.08. Tempo Automation recently announced commencement of Nasdaq delisting proceedings.
    • CarParts.com, Inc. (NASDAQ:PRTS) fell 22.2% to $2.6050 following weak quarterly sales.
    • GeneDx Holdings Corp. (NASDAQ:WGS) declined 21.7% to $2.0901 following quarterly results.
    • Bit Brother Limited (NASDAQ:BETS) fell 19.2% to $0.0468 after declining around 14% on Monday. The company recently reported pricing of $5.04 million registered direct offering.
    • Lattice Semiconductor Corporation (NASDAQ:LSCC) shares fell 18.2% to $55.07 after the company reported third-quarter financial results and issued weak sales forecast for the fourth quarter.
    • Annovis Bio, Inc. (NYSE:ANVS) shares fell 16.7% to $6.79 after the company announced launch of a proposed public offering.
    • Spirit Airlines, Inc. (NYSE:SAVE) dipped 16.2% to $10.94 following quarterly results.
    • Catalent, Inc. (NYSE:CTLT) fell 16% to $33.54.
    • Dorman Products, Inc. (NASDAQ:DORM) declined 16% to $61.14 after the company posted downbeat earnings and lowered FY23 outlook.
    • JetBlue Airways Corporation (NASDAQ:JBLU) tumbled 14.2% to $3.5999 after reporting third-quarter results. The company also said it sees a wider loss for FY23.
    • TETRA Technologies, Inc. (NYSE:TTI) fell 14.2% to $4.79 following weak quarterly results.
    • Chegg, Inc. (NYSE:CHGG) fell 12.7% to $7.74 after the company reported third-quarter financial results and issued fourth-quarter guidance.
    • Orgenesis Inc. (NASDAQ:ORGS) fell 12.4% to $0.71. Orgenesis announced withdrawal of its earlier announced proposed underwritten public offering due to market conditions.
    • ZoomInfo Technologies Inc. (NASDAQ:ZI) dipped 12% to $13.66 following quarterly results.
    • e.l.f. Beauty, Inc. (NYSE:ELF) declined 11.9% to $90.81.
    • PriceSmart, Inc. (NASDAQ:PSMT) dipped 11.2% to $63.65 following weak earnings.
    • V.F. Corporation (NYSE:VFC) shares fell 11.2% to $15.21 after the company reported downbeat second-quarter earnings and withdrew its full-year guidance.
    • Hubbell Incorporated (NYSE:HUBB) declined 10.5% to $253.63 following weak earnings.
    • MicroCloud Hologram Inc. (NASDAQ:HOLO) shares fell 7.7% to $0.7201 after surging around 38% on Monday.
    • BP p.l.c. (NYSE:BP) shares fell 5.2% to $36.33 following weaker-than-expected third-quarter profit.

    Now Read This: Top 3 Consumer Stocks That Could Sink Your Portfolio In Q4

    Get the next $AIRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIRE
    $ANET
    $ANVS
    $ATXI

    CompanyDatePrice TargetRatingAnalyst
    e.l.f. Beauty Inc.
    $ELF
    4/3/2026$68.00In-line
    Evercore ISI
    e.l.f. Beauty Inc.
    $ELF
    4/2/2026$68.00In-line
    Evercore ISI
    Arista Networks Inc.
    $ANET
    3/31/2026$161.00Buy
    Truist
    BP p.l.c.
    $BP
    3/24/2026$49.40Equal-Weight → Overweight
    Morgan Stanley
    JetBlue Airways Corporation
    $JBLU
    3/24/2026$4.50Market Perform
    BMO Capital Markets
    BP p.l.c.
    $BP
    3/20/2026$45.30Reduce → Hold
    HSBC Securities
    Arista Networks Inc.
    $ANET
    3/12/2026$170.00Buy
    TD Cowen
    JetBlue Airways Corporation
    $JBLU
    3/2/2026$7.00Underweight → Equal Weight
    Barclays
    More analyst ratings

    $AIRE
    $ANET
    $ANVS
    $ATXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lattice Wins Multiple 2026 Cybersecurity Excellence Awards

    Lattice Semiconductor (NASDAQ:LSCC), the low power programmable leader, today announced it was named a multi-award winner at the 2026 Cybersecurity Excellence Awards for its security leadership. The Lattice MachXO5™-NX TDQ FPGA family was recognized in the Post-Quantum Cryptography (PQC) category for being the industry's first FPGA family to deliver CNSA-2.0 compliant PQC, crypto agility, and a hardware Root of Trust. In addition, the Lattice Cyber Resilience Program won in the Best Cybersecurity Awareness Program category with its continued comprehensive educational framework to help organizations embed cyber resilience into their architectures and development practices. "From post-qua

    4/2/26 4:00:00 PM ET
    $LSCC
    Semiconductors
    Technology

    Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

    Appointments support Harmony's next phase of growth and long‑term value creation Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Directors, including the appointment of Troy Ignelzi as a director and the nomination of Geno J. Germano as a director for election at Harmony's 2026 Annual Meeting of Shareholders. Mr. Anastasiou previously served on Harmony Biosciences' Board of Directors, where he contributed strategic insight across the business during a period of continued growth and operational evolution. He brings more than three decades of experience building and leading biotechn

    4/2/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

    MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the issuance of U.S. Patent No. 12,582,632 B2, covering prevention and treatment of neurological injuries arising from brain infections through the administration of buntanetap or related compounds. The role of infectious agents in the development of AD has gained significant scientific attention in recent years. Research emerging from the brain microbiome studies has dem

    4/2/26 7:30:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIRE
    $ANET
    $ANVS
    $ATXI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIRE
    $ANET
    $ANVS
    $ATXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Kutzman Thomas J Jr

    3 - reAlpha Tech Corp. (0001859199) (Issuer)

    4/2/26 7:09:18 PM ET
    $AIRE
    Real Estate
    Finance

    SEC Form 4 filed by Bellon Christine

    4 - Beam Therapeutics Inc. (0001745999) (Issuer)

    4/2/26 5:27:06 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Cavanagh Bethany J

    4 - Beam Therapeutics Inc. (0001745999) (Issuer)

    4/2/26 5:22:20 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIRE
    $ANET
    $ANVS
    $ATXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on e.l.f. Beauty with a new price target

    Evercore ISI initiated coverage of e.l.f. Beauty with a rating of In-line and set a new price target of $68.00

    4/3/26 10:44:59 AM ET
    $ELF
    Package Goods/Cosmetics
    Consumer Discretionary

    Evercore ISI initiated coverage on e.l.f. Beauty with a new price target

    Evercore ISI initiated coverage of e.l.f. Beauty with a rating of In-line and set a new price target of $68.00

    4/2/26 8:09:51 AM ET
    $ELF
    Package Goods/Cosmetics
    Consumer Discretionary

    Truist initiated coverage on Arista Networks with a new price target

    Truist initiated coverage of Arista Networks with a rating of Buy and set a new price target of $161.00

    3/31/26 8:09:23 AM ET
    $ANET
    Computer Communications Equipment
    Telecommunications

    $AIRE
    $ANET
    $ANVS
    $ATXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AIRE
    $ANET
    $ANVS
    $ATXI
    SEC Filings

    View All

    Director Masterson Ellen H bought $23,880 worth of shares (1,200 units at $19.90), increasing direct ownership by 6% to 20,980 units (SEC Form 4)

    4 - INSPERITY, INC. (0001000753) (Issuer)

    3/11/26 6:39:34 PM ET
    $NSP
    Professional Services
    Consumer Discretionary

    SVP Legal, Gen Counsel & Sec Callens Christian P bought $24,100 worth of shares (1,250 units at $19.28), increasing direct ownership by 4% to 29,600 units (SEC Form 4)

    4 - INSPERITY, INC. (0001000753) (Issuer)

    3/11/26 6:28:20 PM ET
    $NSP
    Professional Services
    Consumer Discretionary

    Director Meister Keith A. bought $13,460,090 worth of shares (169,521 units at $79.40) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/5/26 7:19:34 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    SEC Form DEFA14A filed by Harmony Biosciences Holdings Inc.

    DEFA14A - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)

    4/3/26 8:05:05 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Harmony Biosciences Holdings Inc.

    DEF 14A - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)

    4/3/26 8:00:16 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Galera Therapeutics Inc.

    8-K - Galera Therapeutics, Inc. (0001563577) (Filer)

    4/3/26 6:03:35 AM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIRE
    $ANET
    $ANVS
    $ATXI
    Leadership Updates

    Live Leadership Updates

    View All

    Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

    Appointments support Harmony's next phase of growth and long‑term value creation Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Directors, including the appointment of Troy Ignelzi as a director and the nomination of Geno J. Germano as a director for election at Harmony's 2026 Annual Meeting of Shareholders. Mr. Anastasiou previously served on Harmony Biosciences' Board of Directors, where he contributed strategic insight across the business during a period of continued growth and operational evolution. He brings more than three decades of experience building and leading biotechn

    4/2/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth

    ATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of John Canning as Chief Operating Officer. Mr. Canning is an accomplished medical device executive with more than 25 years of experience leading global operations and technology organizations within complex medical device companies. He brings a track record of scaling organizations, advancing product pipelines, and driving operational excellence across key functions to support commercial growth and product adoption. Prior to joining

    4/1/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    The Vita Coco Company Set to Join S&P SmallCap 600

    NEW YORK, March 20, 2026 /PRNewswire/ -- The Vita Coco Company Inc. (NASD: COCO) will replace TEGNA Inc. (NYSE:TGNA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, March 25. S&P MidCap 400 constituent Nexstar Media Group Inc. (NASD: NXST) has acquired TEGNA in a deal that closed today, March 20. Following is a summary of the change that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorMarch 25, 2026S&P SmallCap 600AdditionThe Vita Coco CompanyCOCOConsumer StaplesMarch 25, 2026S&P SmallCap 600DeletionTEGNATGNACommunication ServicesABOUT S&P DOW JONES INDICESS&P Dow Jones Indice

    3/20/26 6:06:00 PM ET
    $COCO
    $NXST
    $SPGI
    Beverages (Production/Distribution)
    Consumer Staples
    Broadcasting
    Industrials

    $AIRE
    $ANET
    $ANVS
    $ATXI
    Financials

    Live finance-specific insights

    View All

    Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

    ATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the year ended December 31, 2025 and provides a corporate update. Corporate Highlights from 4Q 2025 to date Initiated patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc, advancing toward U.S. approval.Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors, strengthening leadership and strategic oversight.FemBloc permanent birth control system achieved certification under the Medical Device Single Au

    3/31/26 4:05:00 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    TWO and CrossCountry Mortgage Announce Definitive Merger Agreement

    TWO Stockholders to Receive $10.80 Per Share in Cash TWO Terminates Prior Agreement with UWM Holdings Corporation TWO ((Two Harbors Investment Corp., NYSE:TWO), an MSR-focused REIT and one of the largest servicers of conventional mortgages in the country through its wholly-owned subsidiary RoundPoint Mortgage Servicing LLC, and CrossCountry Intermediate Holdco, LLC, an affiliate of CrossCountry Mortgage, LLC ("CrossCountry" or "CCM") today announced that they have entered into a definitive merger agreement pursuant to which CrossCountry will acquire all of the outstanding shares of TWO common stock for $10.80 per share in cash. This press release features multimedia. View the full rele

    3/27/26 7:15:00 AM ET
    $TWO
    $UWMC
    Real Estate Investment Trusts
    Real Estate
    Finance: Consumer Services
    Finance

    Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

    Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up Corrected M-AAT Comprised 94% of Total AAT with a Concomitant 84% Reduction in Mutant Z-AAT Following BEAM-302 60 mg Treatment Post-treatment Inducibility of AAT Observed During Respiratory Infection with a Patient Reaching ~30 µM Total AAT, Retaining 95% M-AAT Composition Well-tolerated Safety Profile Observed with Single Doses of BEAM-302 up to 75 mg; Safety Consistent Across Single-dose Part A and Part B Cohorts 60 mg Selected as Optimal Biological Dose, Supported by Strong Safety and E

    3/25/26 7:00:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIRE
    $ANET
    $ANVS
    $ATXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Wolfspeed Inc.

    SC 13G/A - WOLFSPEED, INC. (0000895419) (Subject)

    12/6/24 11:56:48 AM ET
    $WOLF
    Semiconductors
    Technology

    Amendment: SEC Form SC 13G/A filed by Pinterest Inc.

    SC 13G/A - PINTEREST, INC. (0001506293) (Subject)

    12/6/24 10:11:26 AM ET
    $PINS
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13G filed by Spirit Airlines Inc.

    SC 13G - Spirit Airlines, Inc. (0001498710) (Subject)

    12/6/24 9:37:58 AM ET
    $SAVE
    Air Freight/Delivery Services
    Consumer Discretionary